All the news Showing 10 of 676 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources HCV treatment feasible and effective in sub-Saharan Africa Keith Alcorn / 17 April 2018 A 12-week course of sofosbuvir/ledipasvir proved highly effective in a sub-Saharan African setting, results of a study carried out in Rwanda show. The findings were presented on Friday at the ... 8-week treatment for hepatitis C with Maviret highly effective in people without cirrhosis Keith Alcorn / 13 April 2018 An eight-week course of treatment with the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C infection in people without cirrhosis, results of two real-world studies presented at the ... Eight weeks of treatment with Epclusa cured almost all people with HCV receiving opioid substitution therapy Keith Alcorn / 12 April 2018 An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area, ... New affordable hepatitis C combination shows 97% cure rate Keith Alcorn / 12 April 2018 The combination of sofosbuvir and the new NS5A inhibitor ravidasvir cured 97% of people with hepatitis C in a study carried out in Malaysia, and could provide a safe and ... NICE nod for Gilead’s pan-genotypic hepatitis C therapy PharmaTimes / 21 February 2018 Sofosbuvir/ledipasvir for 8 weeks cures acute HCV in people with HIV Liz Highleyman / 28 November 2017 An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to a sustained response in all people with HIV and genotype 1 or 4 hepatitis C virus (HCV) in the SWIFT-C study, according ... New three-drug HCV regimen shows nearly 100% response in 6, 8 weeks Healio Hepatology / 30 October 2017 Hepatitis C halved in Spanish people living with HIV in one year due to treatment Keith Alcorn / 27 October 2017 Spain is making dramatic progress towards eliminating hepatitis C in people living with HIV because of widespread use of direct-acting antivirals, Juan Berenguer of Hospital Gregorio Marañón, Madrid, reported on Friday at the ... Maviret cures most people with HCV genotype 3 and those with cirrhosis Liz Highleyman / 24 October 2017 Glecaprevir and pibrentasvir, the two drugs in the recently approved Maviret co-formulation, demonstrated high sustained response rates for people with chronic hepatitis C virus (HCV) genotype 3 and for people with liver ... European and US regulators approve AbbVie's new combo for all hepatitis C genotypes Liz Highleyman / 08 August 2017 The European Commission and the US Food and Drug Administration (FDA) last week approved AbbVie's new combination pill for people with hepatitis C virus (HCV) genotypes 1 to 6, to ... ← Prev12345...68Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive